Get the StoQuant digest — free
Free StoQuant digest by email. No account needed.
See today's research picks.
ALC vs GYRE — Stock Comparison
Compare ALC and GYRE side-by-side on StoQuant: ALC Q-Score 37 vs GYRE 42; analyst signal 40 vs —. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- ALC — Alcon Inc. · Health Care · market cap $33.77B · Q-Score verdict Sell (37.0, grade D) · analyst signal 40/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: valuation 49/100, technicals 37/100 · weakest signals: competitive moat 29/100, analyst consensus 2/100. Full ALC research.
- GYRE — Gyre Therapeutics Inc. Common Stock · Health Care · market cap $713M · Q-Score verdict Hold (42.0, grade C) · strongest signals: earnings quality 78/100, valuation 49/100 · weakest signals: technicals 31/100, competitive moat 13/100. Full GYRE research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: ALC research · GYRE research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →
Register founding interest — Pro $29/mo or Power $79/mo
Paid plans aren’t for sale yet. Leave your email to lock founding pricing (Pro $29, Power $79); we’ll reach out personally.